A Phase 2/3 Study of SYR-322 as an Add-on to an Alpha-Glucosidase Inhibitor
Not Applicable
- Conditions
- Type 2 diabetes mellitus
- Registration Number
- JPRN-UMIN000001381
- Lead Sponsor
- Takeda Pharmaceutical Company Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 210
Inclusion Criteria
Not provided
Exclusion Criteria
The subject has taken any antidiabetic medications except Alpha-glucosidase inhibitors within the last 4 weeks prior to the initiation of screening period(week -8) and during screening period.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method